Ophthalmology
Latest news
87 articles · 20 / page
Influence of Sleep, Physical Activity, and Sedentary Behavior on Cataract Risk: Insights from the UK Biobank Study
A large UK Biobank study demonstrates that poor sleep, low physical activity, and high sedentary behavior independently and jointly increase cataract risk, with lifestyle modifications reducing incidence.
Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients
A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.
Decoding the Blink: How Segmental Control of the Orbicularis Oculi Could Enable Blink Neuroprostheses
UCLA engineers and ophthalmologists mapped segmental, task-dependent activation of the orbicularis oculi during five closure behaviors, defining a roadmap for targeted neurostimulation to restore protective blinking in patients with eyelid
Alcon’s Tryptyr: A New Neuromodulatory Approach for Rapid Dry Eye Relief
Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.
FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review
The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.
Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials
Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.
GLP-1 Receptor Agonists Linked to Early Risk of Optic Nerve Damage: A Case-Control Study Analysis
GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.
Browse by specialty
Open language-specific specialty feeds and department pages.